The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the ...
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Prothena (PRTA) to $110 from $94 and keeps an Overweight rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback